Attorneys for Fox Corp. asked a Delaware judge Friday to dismiss a shareholder lawsuit seeking to hold current and former company officials personally liable for the financial fallout stemming from Fox News reports regarding alleged vote rigging in the 2020 election. Five New York City public employee pension funds, along with Oregon’s public employee retirement fund, allege that former chairman Rupert Murdoch and other Fox Corp. leaders deliberately turned a blind eye to liability risks posed by reporting false claims of vote rigging by election technology companies Dominion Voting Systems and Smartmatic USA. Smartmatic is suing Fox News for defamation in New York, alleging damages of $2.7 billion. It recently settled a lawsuit in the District of Columbia against One America News Network, another conservative outlet, over reports of vote fraud. Dominion also filed several defamation lawsuits against those who spread conspiracy theories blaming its election equipment for Donald Trump’s loss in 2020. Last year, Fox News settled a defamation lawsuit filed by Dominion in Delaware for $787 million. The shareholder plaintiffs also allege that Fox corporate leaders ignored “red flags” about liability arising from a 2017 report suggesting that Seth Rich , a Democratic National Committee staffer, may have been killed because he had leaked Democratic party emails to Wikileaks during the 2016 presidential campaign. Rich, 27, was shot in 2016 in Washington, D.C., in what authorities have said was an attempted robbery. Fox News retracted the Seth Rich story a week after its initial broadcast, but Rich’s parents sued the network for falsely portraying their son as a criminal and traitor. Fox News settled the lawsuit in 2020 for “millions of dollars,” shortly before program hosts Lou Dobbs and Sean Hannity were to be deposed, according to the shareholder lawsuit. Joel Friedlander, an attorney for the institutional shareholders, argued that Fox officials waited until the company’s reporting about Rich became a national scandal before addressing the issue. Similarly, according to the shareholders, corporate officials, including Rupert Murdoch and his son, CEO Lachlan Murdoch, allowed Fox News to continue broadcasting false narratives about the 2020 election, despite internal communications suggesting that they knew there was no evidence to support the conspiracy theories. “The Murdochs could have minimized future monetary exposure, but they chose not to,” Friedlander said. Instead, he argued, they engaged in “bad-faith decision making” with other defendants in a profit-driven effort to retain viewers and remain in Trump’s good graces. “Decisions were made at the highest level to promote pro-Trump conspiracy theories without editorial control,” Friedlander said. Defense attorneys argue that the case should be dismissed because the plaintiffs filed their lawsuit without first demanding that the Fox Corp. board take action, as required under Delaware law. They say the plaintiffs also failed to demonstrate that a pre-suit demand on the Fox board would have been futile because at least half of the directors face a substantial likelihood of liability or are not independent of someone who does. Beyond the “demand futility” issue, defense attorneys also argue that allegations that Fox officials breached their fiduciary duties fail to meet the pleading standards under Delaware and therefore should be dismissed. Defense attorney William Savitt argued, for example, that neither the Rich settlement, which he described as “immaterial,” nor the allegedly defamatory statements about Dominion and Smartmatic constitute red flags putting directors on notice about the risk of defamation liability. Nor do they demonstrate that directors acted in bad faith or that Fox “utterly failed” to implement and monitor a system to report and mitigate legal risks, including defamation liability risk, according to the defendants. Savitt noted that the Rich article was promptly retracted, and that the settlement included no admission of liability. The Dominion and Smartmatic statements, meanwhile, gave rise themselves to the currently liability issues and therefore can not serve as red flags about future liability risks, according to the defendants. “A ‘red flag’ must be what the term commonly implies — warning of a risk of a liability-causing event that allows the directors to take action to avert the event, not notice that a liability-causing event has already occurred,” defense attorneys wrote in their motion to dismiss. Defense attorneys also say there are no factual allegations to support claims that Fox officials condoned illegal conduct in pursuit of corporate profits, or that they deliberately ignored their oversight responsibilities. They note that a “bad outcome” is not sufficient to demonstrate “bad faith.” Vice Chancellor J. Travis Laster is expected to rule within 90 days.

Every new year comes with changes for everyone, and Social Security won’t be the exception. According to the federal agency, in less than two weeks the Social Security system will see two major changes that will directly impact retirees and other beneficiaries in the country. While some Social Security changes only affect specific groups of people, others affect a large number of existing or prospective claimants. As 2025 approaches, there are two significant shifts to be mindful of concerning the latter. Benefits are worth learning about even if you aren’t receiving them right now since they can still be important for your retirement plans in the future. The SSA announced two important surprises that will impact retirees in January 2025 Monthly paychecks will increase for more than 72 million beneficiaries In 2025, the biggest shift to Social Security payouts should be positive. The Social Security cost-of-living adjustment (COLA) will increase the monthly income for all current recipients. It is important to note that the purpose of the annual COLA is to counteract the impacts of inflation. The cost of most products and services, including housing, food, and clothing, appears to be rising gradually. Additionally, it has a greater effect on people who rely on fixed incomes like Social Security. The good news is that starting in January 2025 , recipients can anticipate a 2.5% rise in their monthly benefits. Although a 2.5% increase may be worse, it is less than the average COLA since it became annual in 1975. Benefits staying the same have happened a few times, but that is more of an exception than the rule. The last 10 COLAs are listed below: Social Security calculates the COLA for the following year using the inflation figures for July, August, and September of the previous year. Inflation hasn’t been as high as it has been in recent years, although the 2.5% COLA seems reasonable. I’m sure many retirees don’t mind making this sacrifice. Beneficiaries will have to pay more taxes on their Social Security paychecks A great deal of American workers pay Social Security payroll taxes throughout their working lives. If you have an employer, you and your spouse each pay 6.2% of the 12.4% Social Security tax. If you work for yourself, you are responsible for the entire 12.4%. The good news is that some workers’ earnings may not be subject to Social Security payroll taxes up to a certain amount, known as the wage base limit. The wage base limit was set at $168,600 in 2024, but it will increase to $176,100 in 2025. This means that the higher incomes of certain workers will be subject to Social Security payroll taxes. For example, if your income in 2024 is $175,000, the SSA will exempt around $6,400 from your payroll taxes. On the other hand, because $175,000 is below the new earnings base limit , all of it will be taxable in 2025. Here you will find the last ten wage limits in the US: For those who want to obtain the highest monthly benefit ($5,108 in 2025), it is crucial to understand the yearly wage base limit in addition to the tax issues. You must earn more than the salary base limit during the 35 years that Social Security uses to determine your monthly benefit , and you must wait until 70 (the latest age at which benefits grow by waiting) to be eligible for the maximum amount. Although current Social Security claimants are not directly impacted by wage base limits, it is nonetheless worthwhile to stay updated on yearly adjustments as they can provide insight into the program’s direction and overall health.

Huge Australian crocodile made famous by cameo role in Crocodile Dundee dies

Calls Mount For Arch Manning to Replace Quinn Ewers Amid Injury ConcernsNoneFolk Maritime expands sustainability and connectivity in Middle East shipping

The AP Top 25 men’s college basketball poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . HOUSTON (AP) — Addison Patterson’s 25 points helped Northwestern State defeat Houston Christian 64-57 on Saturday night. Patterson also added five rebounds and three steals for the Demons (5-5, 2-0 Southland Conference). Jon Sanders shot 5 of 9 from the field, including 2 for 4 from 3-point range, and went 5 for 5 from the line to add 17 points. Willie Williams shot 5 of 6 from the field to finish with 10 points, while adding 11 rebounds. Bryson Dawkins finished with 13 points for the Huskies (3-7, 1-1). D’Aundre Samuels added nine points for Houston Christian. Julian Mackey also had nine points. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .

East Carolina wins 71-64 over Stetson

OWINGS MILLS, Md. (AP) — Fresh off one of its best showings of the season, the Baltimore defense now has another problem to worry about. Roquan Smith missed practice again Friday because of a hamstring injury. Although the Ravens didn't officially rule him or anyone else out — they don't play until Monday night — the All-Pro linebacker's status seems dicey. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.CARSON, Calif. — The LA Galaxy finished 26th in the 29-team Major League Soccer standings just one season ago, and their biggest supporters boycotted certain matches to protest a decade of poor performance. The most successful club in league history seemed light years away from its luminous prime. When the Galaxy raised the MLS Cup again Saturday amid confetti and fireworks, their spectacular transformation was complete. In only one year, a team that was profoundly lost had rediscovered its peerless championship pedigree. "We won this trophy, and it's finally back where it belongs," striker Dejan Joveljic said. Joseph Paintsil and Joveljic scored in the first half, and the Galaxy won their record sixth MLS Cup championship with a 2-1 victory over the New York Red Bulls. After striking twice in the first 13 minutes of the final, the Galaxy nursed their lead through a scoreless second half to raise their league's biggest trophy for the first time since 2014. People are also reading... MLS' most successful franchise struggled through most of the ensuing years, but everything changed after LA spent smartly in the offseason to build a high-scoring new lineup topped by Paintsil, Joveljic and Gabriel Pec. The Galaxy finished second in the Western Conference and streaked through the postseason with an MLS playoff-record 18 goals in five games to win another crown. "I'm just so proud of this group after the challenges that we (had) and the way they bounced back and competed as a group," Galaxy coach Greg Vanney said. "We spent a lot of energy at the start, but I'm just so proud of these guys. They've cemented themselves as legends in this club." The Galaxy even won this title without perhaps their most important player. Riqui Puig, the playmaking midfielder from Barcelona who ran their offense impressively all season long, tore a ligament in his knee last week in the conference final. Puig watched this game in a suit, but the Catalan catalyst's teammates hadn't forgotten him: After his replacement, Gastón Brugman, set up LA's opening goal with a superb pass in the ninth minute, Paintsil held up Puig's jersey to their roaring fans during the celebration. "I was really waiting for this moment," said Paintsil, who scored his 14th goal of an impressive season. "I'm much more, 10 times faster than them, and Gaston saw the space. ... It was really a good thing. We did it for Riqui, and we did it for our family that came, and our supporters." Just four minutes later, Joveljic sprinted past four New York defenders and chipped home his 21st goal. Brugman was named the MLS Cup MVP after a commanding performance in midfield. The Uruguayan hadn't started a match for the Galaxy since Oct. 5 after an injury-slowed season, playing only as a postseason substitute before the final. "I dreamed of that yesterday, of something I could give to the team," Brugman said of his pass to Paintsil. "Today, it happened." Sean Nealis scored for the seventh-seeded Red Bulls, whose improbable postseason charge ended one win shy of their first Cup championship. With the league's youngest roster, New York fell just short of becoming the lowest-seeded team to win the tournament under first-year German coach Sandro Schwarz. "I love these guys," Schwarz said. "Some guys, they are crying. In the big picture, that's a start. Sometimes when you lose the final, it's tough, but you use this experience to create the next energy, the next intensity." Galaxy goalkeeper John McCarthy made four saves to win his second MLS title in three seasons, but Nealis beat the 2022 MLS Cup MVP in the 28th minute when he volleyed from the penalty area. The second half was lively: Red Bulls captain Emil Forsberg hit the outside of the post in the 72nd minute, while Pec and Galaxy substitute Marco Reus nearly converted chances a few moments later. The ball got loose in the Galaxy's penalty area in the third minute of extra time, but two Red Bulls couldn't finish. After Galaxy owner Phil Anschutz received the MLS Cup that bears his name because of his steady financial support of the league during its shaky years, Galaxy captain Maya Yoshida carried the trophy to his teammates for the celebration. The Galaxy extended their lead over DC United (4) for the most MLS Cup championships in league history. The Red Bulls remain one of three original MLS franchises never to win the title, along with FC Dallas and the New England Revolution. The Galaxy finished 17-0-3 this season at their frequently renamed suburban stadium, where the sellout crowd of 26,812 for the final included several robust cheering sections of Red Bulls supporters hoping to see their New Jersey-based club's breakthrough. But this season was about the Galaxy's rebirth. The club famous for employing global stars from David Beckham and Zlatan Ibrahimovic to Robbie Keane and Javier "Chicharito" Hernández swiftly turned itself into a contender again by acquiring young talents without international fame. The Galaxy signed Pec from Brazil and grabbed Paintsil, a Ghanaian playing in Belgium. The duo combined with Joveljic to form a potent attack with orchestration from Puig, one of MLS' best players. "Losing a guy like Riqui after the performance he put in all season was devastating," McCarthy said. "Even if he wasn't on the field, we did it for him." Be the first to know Get local news delivered to your inbox!

GREENSBORO, N.C. (AP) — Ryan Forrest's 30 points led N.C. A&T over North Carolina Central 85-72 on Saturday. Forrest shot 12 of 18 from the field, including 2 for 4 from 3-point range, and went 4 for 7 from the line for the Aggies (4-10). Landon Glasper scored 25 points while going 7 of 17 from the floor, including 5 for 12 from 3-point range, and 6 for 6 from the line. Jahnathan Lamothe went 3 of 7 from the field (1 for 4 from 3-point range) to finish with nine points, while adding eight rebounds. The Aggies stopped an eight-game skid with the win. Po'Boigh King finished with 21 points for the Eagles (6-10). Keishon Porter added 11 points and seven rebounds for North Carolina Central. Dionte Johnson also recorded 11 points. N.C. A&T took the lead with 1:28 remaining in the first half and never looked back. The score was 46-39 at halftime, with Glasper racking up 18 points. Forrest scored 18 points in the second half to help lead the way as N.C. A&T went on to secure a victory, outscoring North Carolina Central by six points in the second half. NEXT UP Up next for N.C. A&T is a matchup Thursday with Elon at home. North Carolina Central hosts Saint Andrews (NC) on Tuesday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Canadian Pacific Kansas City Ltd. stock falls Friday, underperforms market

Difficult but not impossible: Lions keep faith as they face Vietnam in second leg of ASEAN Championship semisDaqo New Energy (NYSE:DQ) Shares Gap Down – Here’s Why

Peripheral T Cell Lymphomas Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Celleron Therapeutics, Myeloid Therapeutics, Astex Pharma 12-23-2024 11:04 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral T Cell Lymphomas pipeline constitutes 40+ key companies continuously working towards developing 40+ Peripheral T Cell Lymphomas treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Peripheral T Cell Lymphomas Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. "Peripheral T Cell Lymphomas Pipeline Insight, 2024 [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral T Cell Lymphomas Market. Some of the key takeaways from the Peripheral T Cell Lymphomas Pipeline Report: * Companies across the globe are diligently working toward developing novel Peripheral T Cell Lymphomas treatment therapies with a considerable amount of success over the years. * Peripheral T Cell Lymphomas companies working in the treatment market are HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others, are developing therapies for the Peripheral T Cell Lymphomas treatment * Emerging Peripheral T Cell Lymphomas therapies in the different phases of clinical trials are- HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others are expected to have a significant impact on the Peripheral T Cell Lymphomas market in the coming years. * In December 2024, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced new data showcasing significant improvements in quality of life for patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. The findings were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. * In December 2024, Secura Bio, Inc. (Secura Bio), an integrated pharmaceutical company focused on the global development and commercialization of effective oncology therapies, presented two posters at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The first poster showcased new data from the Company's Phase 2 PRIMO trial of duvelisib for treating relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL), while the second poster outlined the clinical design for the planned Phase 3 randomized trial of duvelisib in R/R nodal T-follicular helper cell lymphoma (TERZO Trademark ). Peripheral T Cell Lymphomas Overview Peripheral T-cell lymphomas (PTCL) are a diverse group of aggressive blood cancers that develop in T-cells, a type of white blood cell involved in immune function. Unlike other types of lymphoma, PTCL originates outside the bone marrow, typically in lymph nodes, spleen, or other tissues. Symptoms may include swollen lymph nodes, fever, weight loss, night sweats, and skin rashes. PTCL is rare and often more difficult to treat compared to other lymphomas. Treatment options may include chemotherapy, immunotherapy, stem cell transplants, and targeted therapies, depending on the specific subtype and stage of the disease. Get a Free Sample PDF Report to know more about Peripheral T Cell Lymphomas Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight [ https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Emerging Peripheral T Cell Lymphomas Drugs Under Different Phases of Clinical Development Include: * HBI-8000: HUYA Bioscience International * AT-104: Applied Therapeutics * Auto 5: Autolus * AK 104: Akeso Biopharma * Tolinapant: Astex Pharmaceuticals * Duvelisib: Secura Bio * Lacutamab: Innate Pharma * AZD 4205: Dizal Pharmaceutical * Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology Peripheral T Cell Lymphomas Route of Administration Peripheral T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as * Subcutaneous * Intravenous * Oral * Intramuscular * Intra-tumoral * Molecule Type Peripheral T Cell Lymphomas Molecule Type Peripheral T Cell Lymphomas Products have been categorized under various Molecule types, such as * Monoclonal antibodies * Immunoglobulins * Small molecules * Pyrimidines * Proteins and Peptides * Product Type Peripheral T Cell Lymphomas Pipeline Therapeutics Assessment * Peripheral T Cell Lymphomas Assessment by Product Type * Peripheral T Cell Lymphomas By Stage and Product Type * Peripheral T Cell Lymphomas Assessment by Route of Administration * Peripheral T Cell Lymphomas By Stage and Route of Administration * Peripheral T Cell Lymphomas Assessment by Molecule Type * Peripheral T Cell Lymphomas by Stage and Molecule Type DelveInsight's Peripheral T Cell Lymphomas Report covers around 40+ products under different phases of clinical development like * Late-stage products (Phase III) * Mid-stage products (Phase II) * Early-stage product (Phase I) * Pre-clinical and Discovery stage candidates * Discontinued & Inactive candidates * Route of Administration Further Peripheral T Cell Lymphomas product details are provided in the report. Download the Peripheral T Cell Lymphomas pipeline report to learn more about the emerging Peripheral T Cell Lymphomas therapies [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Some of the key companies in the Peripheral T Cell Lymphomas Therapeutics Market include: Key companies developing therapies for Peripheral T Cell Lymphomas are - Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Secura Bio, Genor Biopharma Co., Ltd., CerRx, Inc., Dizal Pharmaceuticals, Kura Oncology, Inc., Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics, C4 Therapeutics, Kymera Therapeutics, Daiichi Sankyo, SciTech Development LLC, Sorrento Therapeutics, Bristol-Myers Squibb, Shanghai Yingli Pharmaceutical, Ono Pharmaceutical, and others. Peripheral T Cell Lymphomas Pipeline Analysis: The Peripheral T Cell Lymphomas pipeline report provides insights into * The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T Cell Lymphomas with aggregate therapies developed by each company for the same. * It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T Cell Lymphomas Treatment. * Peripheral T Cell Lymphomas key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. * Peripheral T Cell Lymphomas Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. * Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T Cell Lymphomas market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Peripheral T Cell Lymphomas drugs and therapies [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Peripheral T Cell Lymphomas Pipeline Market Drivers * Increase in incidences of PTCL, rising investment for the development of advanced technologies, surge in government initiatives to promote research and awareness about the disease are some of the important factors that are fueling the Peripheral T Cell Lymphomas Market. Peripheral T Cell Lymphomas Pipeline Market Barriers * However, high cost associated with the treatment, lack of skilled professionals for early diagnosis of the disease and other factors are creating obstacles in the Peripheral T Cell Lymphomas Market growth. Scope of Peripheral T Cell Lymphomas Pipeline Drug Insight * Coverage: Global * Key Peripheral T Cell Lymphomas Companies: HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others * Key Peripheral T Cell Lymphomas Therapies: HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others * Peripheral T Cell Lymphomas Therapeutic Assessment: Peripheral T Cell Lymphomas current marketed and Peripheral T Cell Lymphomas emerging therapies * Peripheral T Cell Lymphomas Market Dynamics: Peripheral T Cell Lymphomas market drivers and Peripheral T Cell Lymphomas market barriers Request for Sample PDF Report for Peripheral T Cell Lymphomas Pipeline Assessment and clinical trials [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Table of Contents 1. Peripheral T Cell Lymphomas Report Introduction 2. Peripheral T Cell Lymphomas Executive Summary 3. Peripheral T Cell Lymphomas Overview 4. Peripheral T Cell Lymphomas- Analytical Perspective In-depth Commercial Assessment 5. Peripheral T Cell Lymphomas Pipeline Therapeutics 6. Peripheral T Cell Lymphomas Late Stage Products (Phase II/III) 7. Peripheral T Cell Lymphomas Mid Stage Products (Phase II) 8. Peripheral T Cell Lymphomas Early Stage Products (Phase I) 9. Peripheral T Cell Lymphomas Preclinical Stage Products 10. Peripheral T Cell Lymphomas Therapeutics Assessment 11. Peripheral T Cell Lymphomas Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Peripheral T Cell Lymphomas Key Companies 14. Peripheral T Cell Lymphomas Key Products 15. Peripheral T Cell Lymphomas Unmet Needs 16 . Peripheral T Cell Lymphomas Market Drivers and Barriers 17. Peripheral T Cell Lymphomas Future Perspectives and Conclusion 18. Peripheral T Cell Lymphomas Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=peripheral-t-cell-lymphomas-pipeline-2024-clinical-trials-assessment-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-celleron-therapeutics-myeloid-therapeutics-astex-pharma ] Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.PARIS (AP) — Paris Saint-Germain failed to score in Ligue 1 for the first time this season as the reigning champion was denied by outstanding goalkeeping from Auxerre's Donovan Léon in a 0-0 draw on Friday. Léon's string of superb saves thwarted PSG’s attacking stars. After a fairly even first 45 minutes, PSG camped in the Auxerre half but could not find a way past León, who made memorable stops from Gonçalo Ramos, Achraf Hakimi, Kang-In Lee, Désiré Nonka-Maho and Randal Kolo Muani. Vitinha saw one curling shot come back off the bar. PSG had 25 shots to Auxerre’s six and 15 corners to Auxerre’s three but the home side still could have stolen all three points, as PSG keeper Gianluigi Donnarumma had to make a smart stop from Hamed Traorè. PSG remained eight points clear on top of Ligue 1. Auxerre was eighth. David scores brace for Lille Canadian striker Jonathan David scored two and made another as Lille brushed past Brest 3-1 to extend its unbeaten run to 10 games in Ligue 1. The last time Lille lost to Brest at home was in 1989 and that long run never looked likely to fall as David turned in a man-of-the-match performance at Stade Pierre-Mauroy. He put Lille ahead from the penalty spot after nine minutes and he got away from his marker and crossed for Hákon Haraladsson to clip home a second just before halftime. Ludovic Ajorque got one back for Brest early in the second half but David restored Lille’s two-goal cushion when he pounced on a loose ball to slide home his team’s third. David’s goals took his season total to 17 in 23 games. They were his 10th and 11th in the league and lift him to the top of the Ligue 1 goal-scoring chart. Marseille was second ahead of Lille and Monaco on goal difference. AP soccer: https://apnews.com/hub/soccerTrump's November election victory has cast doubt on the future of American aid for Ukraine, providing a limited window for billions of dollars in already authorized assistance to be disbursed before he is sworn in next month. The package features drones, ammunition for precision HIMARS rocket launchers, and equipment and spare parts for artillery systems, tanks and armored vehicles, the Pentagon said in a statement. Trump met in Paris earlier Saturday with Ukrainian President Volodymyr Zelensky, who said any resolution of the war with Russia should be a "just" settlement that includes "strong security guarantees for Ukraine." The meeting was of huge importance to Zelensky, given fears in Kyiv that Trump may urge Ukraine to make concessions to Moscow. The latest aid will be funded via the Ukraine Security Assistance Initiative, under which military equipment is procured from the defense industry or partners rather than drawn from American stocks, meaning it will not immediately arrive on the battlefield. It follows a $725 million package announced on Monday that included a second tranche of landmines as well as anti-air and anti-armor weapons. The outgoing administration of President Joe Biden is working to get as much aid as possible to Ukraine before Trump -- who has repeatedly criticized US assistance for Kyiv and claimed he could secure a ceasefire within hours -- takes over. Trump's comments have triggered fears in Kyiv and Europe about the future of US aid, and Ukraine's ability to withstand Russian attacks in the absence of further American support. "Our job has been to try and put Ukraine in the strongest possible position on the battlefield so that it is in the strongest possible position at the negotiating table," National Security Advisor Jake Sullivan said Saturday. In the closing weeks of Biden's term, the goal is "a massive surge of assistance and to up the economic pressure on Russia," he said. US Defense Secretary Lloyd Austin on Saturday warned that failure to continue opposing Russia's actions would have dire consequences. "We can continue to stand up to the Kremlin. Or we can let (Russian President Vladimir) Putin have his way -- and condemn our children and grandchildren to live in a world of chaos and conflict," said Austin, who like Sullivan was speaking at the Reagan National Defense Forum in California. "This administration has made its choice. And so has a bipartisan coalition in Congress. The next administration must make its own choice." The defense chief also emphasized the importance of US allies and partners in his remarks -- a contrast to Trump's go-it-alone "America first" world view. "Here is the stark military fact: our allies and partners are huge force multipliers," Austin said. "Ultimately, America is weaker when it stands alone. And America is smaller when it stands apart," he said. "There is no such thing as a safe retreat from today's interwoven world." The United States has spearheaded the push for international support for Ukraine, quickly forging a coalition to back Kyiv after Russia launched its full-scale invasion in 2022 and coordinating aid from dozens of countries. Ukraine's international supporters have since then provided tens of billions of dollars in weapons, ammunition, training and other security aid that has been key to helping Kyiv resist Russian forces. wd/mlm/acb

CARSON, Calif. — Joseph Paintsil and Dejan Joveljic scored in the first half, and the LA Galaxy won their record sixth MLS Cup championship with a 2-1 victory over the New York Red Bulls on Saturday. After striking twice in the first 13 minutes of the final with goals from their star forwards, the Galaxy nursed their lead through a scoreless second half to raise their league's biggest trophy for the first time since 2014. MLS' most successful franchise struggled through most of the ensuing decade, even finishing 26th in the 29-team league last year. But the Galaxy turned everything around this season with a high-scoring new lineup that finished second in the Western Conference and then streaked through the playoffs with a playoff-record 18 goals in five games to win another crown. Sean Nealis scored for the seventh-seeded Red Bulls, whose improbable postseason charge ended one win shy of their first Cup championship. With the league's youngest roster, New York fell just short of becoming the lowest-seeded team to win MLS' playoff tournament under first-year German coach Sandro Schwarz. The Galaxy won this title without perhaps their most important player. Riqui Puig, the playmaking midfielder from Barcelona who ran their offense impressively all season long, tore a ligament in his knee last week in the Western Conference final. Puig watched this game in a suit, but his teammates hadn't forgotten him: After his replacement, Gastón Brugman, set up LA's opening goal with a superb pass, Paintsil held up Puig's jersey to their fans during the celebration. Brugman was named the MLS Cup MVP after a commanding performance in midfield. The Uruguayan hadn't started a match for the Galaxy since Oct. 5, playing only as a postseason substitute before the final. Galaxy goalkeeper John McCarthy made four saves to win his second MLS title in three seasons. He was the MVP of the 2022 MLS Cup Final for the Galaxy's crosstown rival, Los Angeles FC. Paintsil put the Galaxy ahead in the ninth minute when he ran onto that sublime pass from Brugman and pounded home his 14th MLS goal — including four in the playoffs — in the Ghanaian forward's outstanding first season. Just four minutes later, Joveljic sprinted past four New York defenders and chipped home the 21st goal of his outstanding year as the Galaxy's striker. Nealis got New York on the scoreboard in the 28th minute when he volleyed home a ball that got loose in LA's penalty area after a corner. The Galaxy's usually shaky defense gave up another handful of good chances before reaching halftime with a tenuous lead. The second half was lively, but scoreless. Red Bulls captain Emil Forsberg hit the outside of the post in the 72nd minute, while LA's Gabriel Pec and Galaxy substitute Marco Reus nearly converted chances a few moments later. The ball got loose again in the Galaxy's penalty area in the third minute of extra time, but two Red Bulls couldn't finish. The Galaxy bench rushed onto the field and prematurely celebrated a victory in the seventh minute of injury time, only to be herded back off for another 30 seconds of play. After Galaxy owner Phil Anschutz received the MLS Cup that bears his name because of his steady financial support of the league during its shaky years, Galaxy captain Maya Yoshida carried the trophy onto a stage filled with his teammates for a celebration amid fireworks and confetti. The Galaxy extended their lead over DC United (4) for the most MLS Cup championships in league history. The Red Bulls remain one of three original MLS franchises never to win the title, along with FC Dallas and the New England Revolution. The Galaxy's Greg Vanney became the fourth coach to win an MLS title with two clubs. The former Galaxy player also won it all with Toronto in 2017. The Galaxy finished 17-0-3 this season at their frequently renamed suburban stadium, where the sellout crowd of 26,812 for the final included several robust cheering sections of traveling Red Bulls supporters hoping to see their New Jersey-based club's breakthrough on MLS' biggest stage. Just last season, the Galaxy's own supporters boycotted the team at certain matches, fed up with years of mismanagement and no progress. The club famous for employing global stars from David Beckham and Zlatan Ibrahimovic to Robbie Keane and Javier "Chicharito" Hernández swiftly rebuilt itself into a contender this season by spending big to get lesser-known young talents from around the world. The Galaxy signed Pec from Brazil and Paintsil out of Belgium. The duo combined with incumbent Serbian striker Joveljic to form a potent attack that could outscore almost any MLS opponent. But the Galaxy also relied heavily on Puig, their Catalan catalyst and one of MLS' best players. Puig stayed in last week's game after injuring his knee, and he even delivered the decisive pass to Joveljic for the game's only goal. Be the first to know Get local news delivered to your inbox!Will focus on quality public spending: GovernmentGREENSBORO, N.C. (AP) — Ryan Forrest's 30 points led N.C. A&T over North Carolina Central 85-72 on Saturday. Forrest shot 12 of 18 from the field, including 2 for 4 from 3-point range, and went 4 for 7 from the line for the Aggies (4-10). Landon Glasper scored 25 points while going 7 of 17 from the floor, including 5 for 12 from 3-point range, and 6 for 6 from the line. Jahnathan Lamothe went 3 of 7 from the field (1 for 4 from 3-point range) to finish with nine points, while adding eight rebounds. The Aggies stopped an eight-game skid with the win. Po'Boigh King finished with 21 points for the Eagles (6-10). Keishon Porter added 11 points and seven rebounds for North Carolina Central. Dionte Johnson also recorded 11 points. N.C. A&T took the lead with 1:28 remaining in the first half and never looked back. The score was 46-39 at halftime, with Glasper racking up 18 points. Forrest scored 18 points in the second half to help lead the way as N.C. A&T went on to secure a victory, outscoring North Carolina Central by six points in the second half. NEXT UP Up next for N.C. A&T is a matchup Thursday with Elon at home. North Carolina Central hosts Saint Andrews (NC) on Tuesday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .